pharmaphorum

JULY 6, 2021

Nina Garrett, R&D director at Abingdon Health discusses the key role antibody testing is playing in the pandemic and how an integrated approach with vaccines could help normal life resume. This is where antibody tests come in. Neutralising Antibodies. ” .

Antibody 111

Antibody Immune Response Protein Vaccination 111

Medical Xpress

JANUARY 17, 2023

Formed after exposure to a pathogen or vaccine, germinal centers act as a kind of immune system training academy, helping B cells refine their response to the threat.

Immune Response 96

Immune Response Vaccination Vaccine Antibody 96

NY Times

MAY 11, 2022

Antibody levels rose in the children who received it, suggesting the vaccine protects against infection. But the data were gathered before the arrival of Omicron.

Immune Response 62

Immune Response Vaccine Vaccination Antibody 62

Medical Xpress

MARCH 6, 2023

A clinical trial testing a freeze-dried, temperature-stable experimental tuberculosis (TB) vaccine in healthy adults found that it was safe and stimulated both antibodies and responses from the cellular arm of the immune system. Results are published in Nature Communications.

Immune Response 67

Immune Response Vaccination Vaccine Trials 67

The Pharma Data

AUGUST 16, 2021

The study assessed cynomolgus macaques vaccinated with 12µg of either the first or second-generation vaccine candidate. Higher antibody neutralizing capacity was observed with CV2CoV across all selected variants, including the Beta, Delta and Lambda variants.

Immune Response 52

Immune Response Vaccine Vaccination Antibody 52

pharmaphorum

DECEMBER 9, 2021

AstraZeneca’s antibody cocktail for COVID-19, now called Evushield, has become the first drug in the class to be authorised for prevention of infection by the US FDA. The emergency use authorisation (EUA) for Evushield activates a 700,000 order for the antibody from the US government, worth upwards of $726 million.

Antibody 124

Antibody Immune Response Vaccine Vaccination 124

BioSpace

AUGUST 13, 2020

A COVID-19 vaccine candidate developed by Chinese pharmaceutical company Sinopharm triggered antibody-based immune responses in early and mid-stage trials.

Immune Response 132

Immune Response Vaccination Vaccine Antibody 132

Scienmag

OCTOBER 12, 2021

A quick stick in the arm with an approved COVID-19 vaccine elicits a flurry of activity in the body’s immune system. While much work has been done to study the antibodies produced in response to these vaccines, less is known about the response by the immune system’s T cells, which offer longer-term protection against the […].

Immune Response 52

Immune Response Vaccine Vaccination Antibody 52

Scienmag

MARCH 25, 2021

The largest study of its kind to date also found benefit for lactating women BOSTON – In the largest study of its kind to date, researchers at Massachusetts General Hospital, Brigham and Women’s Hospital and the Ragon Institute of MGH, MIT and Harvard have found the new mRNA COVID-19 vaccines to be highly effective in […].

Immune Response 69

Immune Response Vaccination Vaccine Antibody 69

pharmaphorum

OCTOBER 11, 2022

An intranasal formulation of AstraZeneca’s widely-used COVID-19 vaccine Vaxzevria has failed at the first hurdle, after results from a phase 1 trial found it was unable to stimulate a strong immune response to the virus. Other efforts to develop a nasally-delivered COVID-19 vaccine have met with greater success.

Vaccination 116

Vaccination Vaccine Immune Response Development 116

Pharmaceutical Technology

JANUARY 19, 2023

The Korean Ministry of Food and Drug Safety (KMFDS) has granted expanded approval to Novavax partner SK bioscience for the Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), for use as a booster dose in adults aged 18 and above. Nuvaxovid is a protein-based vaccine created from the genetic sequence of the initial SARS-CoV-2 virus strain.

Vaccination 147

Vaccination Vaccine Immune Response Protein 147

The Pharma Data

SEPTEMBER 10, 2020

Pfizer-BioNTech announced Wednesday that preliminary preclinical data from mouse and macaque monkey models showed a strong immune response from its mRNA COVID-19 vaccine. . The study and the data are currently subject to peer review.

Immune Response 52

Immune Response Vaccination Vaccine RNA 52

The Pharma Data

MAY 17, 2021

The investigational COVID-19 vaccine uses the same recombinant protein-based technology as one of Sanofi’s seasonal flu vaccines, along with GSK’s established pandemic adjuvant technology. response in the over-50s, the age group deemed at higher risk for contracting the severe form of the virus. . Phase 2 study ?.

Immune Response 52

Immune Response Vaccination Vaccine Antibody 52

pharmaphorum

JANUARY 13, 2022

Preliminary data from an ongoing trial of AstraZeneca’s COVID-19 vaccine Vaxzevria has shown that a booster dose stimulates an increase in antibodies against Omicron, as well as other variants of the virus, including Alpha, Beta, Delta, and Gamma. billion doses administered. billion doses administered.

Antibody 98

Antibody Immune Response Vaccination Vaccine 98

Medical Xpress

NOVEMBER 8, 2022

New research presented this week at ACR Convergence 2022, the American College of Rheumatology's annual meeting, showed that a higher dose of pneumococcal vaccine safely and effectively improved antibody response in patients receiving rituximab for ANCA-associated vasculitis.

Immune Response 51

Immune Response Vaccination Vaccine Antibody 51

Pharmaceutical Technology

DECEMBER 6, 2022

Evaxion Biotech and ExpreS 2 ion Biotechnologies have entered a vaccine discovery collaboration agreement to co-develop a new cytomegalovirus (CMV) vaccine candidate. CMV represents a critical unmet medical need, and I believe our two companies have the potential to deliver a truly differentiated vaccine.”.

Vaccination 130

Vaccination Vaccine Development Immune Response 130

The Pharma Data

NOVEMBER 10, 2020

Canadian biopharmaceutical company Medicago has announced that its investigational COVID-19 vaccine generated “significant antibody and cellular immune responses” after two doses in all subjects in an early-stage clinical trial. microgram or 15-microgram doses of the vaccine candidate, either alone or with an adjuvant.

Immune Response 40

Immune Response Vaccination Vaccine Clinical Trials 40

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Flavivirus vaccine components. Sanofi is one of the leading patent filers for Flavivirus vaccine components.

Vaccination 130

Vaccination Vaccine Protein Immune Response 130

Pharmaceutical Technology

APRIL 10, 2023

It will also be used for the treatment of people who are not likely to have an adequate immune response to Covid-19 vaccination or for people who are not recommended for Covid-19 vaccination. Evusheld (formerly AZD7442) is a combination of two long-acting antibodies, tixagevimab (AZD8895) and cilgavimab (AZD1061).

Immune Response 264

Immune Response Antibody Vaccine Vaccination 264

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Coronavirus vaccine components. The vaccine also contains other inactive ingredients such as cholesterol.

Vaccination 130

Vaccination Vaccine Containment Immune Response 130

Scienmag

DECEMBER 2, 2021

Peer-reviewed / Randomised Controlled Trial / People Randomised, phase 2 trial of COVID-19 booster vaccines finds seven increase immunity when given 10-12 weeks after two doses of Oxford-AstraZeneca, and six increase immunity following two doses of Pfizer-BioNTech. UK trial involving 2,878 adults […].

Immune Response 68

Immune Response Trials Antibody Vaccination 68

BioPharma Reporter

MARCH 30, 2021

COVID-19 mRNA vaccines are âhighly effectiveâ in producing antibodies against SARS-CoV-2 in pregnant and lactating women; and also confer protective immunity to newborns, according to a new study.

Immune Response 52

Immune Response Vaccination Vaccine Antibody 52

pharmaphorum

FEBRUARY 25, 2021

Pfizer/BioNTech’s mRNA vaccine against COVID is a technical marvel – but the ultra-cool temperatures required for storage and stability has been tricky to handle. A nasal delivery method will also produce an immune response at the point where the virus enters the body.

Vaccination 111

Vaccination Vaccine Immune Response Trials 111

pharmaphorum

MAY 19, 2022

Moderna has joined forces with non-profit organisation IAVI on a third phase 1 trial of its candidate HIV vaccine in Africa, where the burden of the virus is still being keenly felt. There are hopes that its mRNA approach, which proved so effective against COVID-19, could succeed where traditional vaccine technologies have failed in HIV.

Vaccination 145

Vaccination Vaccine Trials Immune Response 145

Pharmaceutical Technology

MARCH 31, 2023

The European Medicines Agency (EMA) has recommended HIPRA’s Covid-19 vaccine , Bimervax, as a Covid-19 booster. Available to people ages 16 years and above who have been vaccinated with a Covid-19 mRNA vaccine, EMA’s Human Medicines Committee concluded the vaccine is ready for marketing authorization in the EU, on 30 March.

Vaccination 277

Vaccination Vaccine Immune Response Antibody 277

Medical Xpress

DECEMBER 9, 2022

People infected with HIV who receive antiretroviral therapy form antibodies against SARS-CoV-2 after being vaccinated against COVID with mRNA vaccines. Their immune response to the vaccination is, however, less strong than that of healthy people. A third vaccination reduces this gap.

Vaccine 54

Vaccine Vaccination Immune Response Antibody 54

Scienmag

MAY 6, 2022

New research being presented at this year’s European Congress on Obesity (ECO) in Maastricht, Netherlands (4-7 May), suggests that adults (aged 18 or older) with severe obesity generate a significantly weaker immune response to COVID-19 vaccination compared to those with normal weight.

Vaccination 59

Vaccination Vaccine Immune Response Antibody 59

Medical Xpress

DECEMBER 1, 2022

In 2021, a group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate containing an adjuvant, a substance that enhances immune responses, elicited durable neutralizing antibody responses to SARS-CoV-2 (..)

Vaccination 68

Vaccination Vaccine Immune Response Containment 68

Pharmaceutical Technology

JUNE 8, 2023

Gritstone bio has reported interim results from an ongoing Phase 1 study evaluating the company’s self-amplifying mRNA (samRNA) vaccine as a boost against Covid-19 (CORAL-BOOST). The Phase I CORAL-BOOST dose-escalation trial (NCT05148962) evaluated Gritstone’s samRNA candidate (GRT-R910) in previously vaccinated healthy older adults.

Vaccination 130

Vaccination Vaccine Immune Response Allergies 130

pharmaphorum

NOVEMBER 8, 2021

A single dose of the COVID-19 monoclonal antibody therapy developing Regeneron reduced the risk of contracting the virus by around 82% for up to eight months, according to new trial data. The rate of COVID-19 vaccination was balanced between the two groups. The rate of COVID-19 vaccination was balanced between the two groups.

Antibody 105

Antibody Vaccination Vaccine Immune Response 105

The Pharma Data

MAY 16, 2021

Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups. High immune response after a single dose in patients with prior infection shows strong booster potential. Global Phase 3 study expected to start in the coming weeks.

Immune Response 52

Immune Response Vaccination Vaccine Trials 52

Scienmag

MAY 26, 2021

In series of samples collected from individuals vaccinated against COVID-19, an ultrasensitive test detected low concentrations of circulating antigen; Following robust production of antibodies, viral protein declined to undetectable levels The carefully orchestrated dance between the immune system and the viral proteins that induce immunity against (..)

Immune Response 54

Immune Response Protein Vaccination Vaccine 54

pharmaphorum

JULY 18, 2022

MBA, managing director at CanSino Biologics Europe, tells us about Convidecia, a single dose SARS-CoV-2 vaccine offered as an injectable and inhalant that allows ease of storage, an alternative option for individuals with needle phobias, and robust elongated CD4 and CD8 cellular response. Morgon, PharmD, LL.M, How it works.

Vaccination 138

Vaccination Vaccine Development Immune Response 138

Scienmag

MARCH 24, 2021

Department of Defense When clinical trials were conducted to determine the immunogenicity — the ability to elicit an immune response — for the first two vaccines marshaled against SARS-CoV-2the virus that causes COVID-19, one group was not among those included: people who have received solid organ […].

Immune Response 78

Immune Response Vaccination Vaccine Antibody 78

pharmaphorum

JANUARY 15, 2021

J&J has announced early trial results that suggest its single-shot coronavirus vaccine provides a sustained response against the virus ahead of a phase 3 trial readout due later this month. Both of these vaccines require two doses, as does the most recently approved shot from Moderna, which is due to arrive in the UK in the spring.

Vaccination 119

Vaccination Vaccine Immune Response Antibody 119

BioSpace

SEPTEMBER 27, 2020

The company posted an interim analysis of its Phase I/IIa trial that showed a single dose of JNJ-78436735 induced a strong neutralizing antibody response in nearly all participants and was well-tolerated.

Immune Response 89

Immune Response Antibody Vaccine Vaccination 89

pharmaphorum

OCTOBER 5, 2021

AstraZeneca has sought emergency use authorisation for its antibody combination AZD7442, following trial results indicating it can prevent symptomatic COVID-19 infection when given to healthy patients. The post AZ files for emergency use of COVID-19 antibody combo in US appeared first on. Initial results from that study were negative.

Antibody 111

Antibody Immune Response Vaccination Vaccine 111